Experimental Bladder Cancer Models for Animals

被引:0
|
作者
Kosan, Murat [1 ]
Mungan, Aydin [2 ]
机构
[1] Baskent Univ, Tip Fak, Urol Anabilim Dali, Konya, Turkey
[2] Bulent Ecevit Univ, Tip Fak, Urol Anabilim Dali, Zonguldak, Turkey
来源
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY | 2015年 / 14卷 / 01期
关键词
Bladder cancer; transitional cell carcinoma; experimental animal models;
D O I
10.4274/uob.283
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Transitional cell carcinoma (TCC) is the most common malignancy of the genitourinary tract and TCC models are being developed over the past decades. Experimental models are needed so that more effective treatments can be developed in preclinical evaluation. Even if, in vitro models are useful for initial development and evaluation of therapeutic agents and modalities, adequate animal models are still essential in the preclinical development of new effective and safe therapies. A great variety of ex vivo and in vivo models has been described in the literature. Chemical carcinogens are most commonly used to induce bladder cancer. Cell culture techniques are also widely used to study different oncological processes. To test potential new drugs in a preclinical setting, a clinically relevant orthotopic bladder tumor model is highly desirable. The aim of this review article was the assessment of different animal models available for the study of bladder carcinogenesis.
引用
收藏
页码:29 / 32
页数:4
相关论文
共 50 条
  • [41] Localized bladder cancer.
    Izawa J.I.
    Grossman H.B.
    Current Treatment Options in Oncology, 2000, 1 (5) : 423 - 432
  • [42] Molecular markers in bladder cancer
    Soria, Francesco
    Krabbe, Laura-Maria
    Todenhoefer, Tilman
    Dobruch, Jakub
    Mitra, Anirban P.
    Inman, Brant A.
    Gust, Kilian M.
    Lotan, Yair
    Shariat, Shahrokh F.
    WORLD JOURNAL OF UROLOGY, 2019, 37 (01) : 31 - 40
  • [43] Metabolic phenotype of bladder cancer
    Massari, Francesco
    Ciccarese, Chiara
    Santoni, Matteo
    Iacovelli, Roberto
    Mazzucchelli, Roberta
    Piva, Francesco
    Scarpelli, Marina
    Berardi, Rossana
    Tortora, Giampaolo
    Lopez-Beltran, Antonio
    Cheng, Liang
    Montironi, Rodolfo
    CANCER TREATMENT REVIEWS, 2016, 45 : 46 - 57
  • [44] Bladder cancer and new drugs
    Massard, C.
    Albouy, B.
    Gross-Goupil, M.
    Ravaud, A.
    BULLETIN DU CANCER, 2010, 97 : S43 - S50
  • [45] Molecular pathways in bladder cancer
    Stephen G. Williams
    John P. Stein
    Urological Research, 2004, 32 : 373 - 385
  • [46] Human papillomavirus and bladder cancer
    LopezBeltran, A
    Escudero, AL
    BIOMEDICINE & PHARMACOTHERAPY, 1997, 51 (6-7) : 252 - 257
  • [47] Molecular pathways in bladder cancer
    Williams, SG
    Stein, JP
    UROLOGICAL RESEARCH, 2004, 32 (06): : 373 - 385
  • [48] Molecular Biology of Bladder Cancer
    Martin-Doyle, William
    Kwiatkowski, David J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 29 (02) : 191 - +
  • [49] Photodynamic management of bladder cancer
    Johansson, A.
    Stepp, H.
    Beyer, W.
    Pongratz, T.
    Sroka, R.
    Bader, M.
    Kriegmair, M.
    Zaak, D.
    Waidelich, R.
    Karl, A.
    Hofstetter, A.
    Stief, C.
    Baumgartner, R.
    12TH WORLD CONGRESS OF THE INTERNATIONAL PHOTODYNAMIC ASSOCIATION: PHOTODYNAMIC THERAPY: BACK TO THE FUTURE, 2009, 7380
  • [50] Value of cemoradiation in bladder cancer
    Weiss, C.
    Sauer, R.
    Roedel, C.
    ONKOLOGE, 2012, 18 (11): : 1003 - +